Benzodiazepines, a class of prescription medications, have played a significant role in managing anxiety and sleep disorders in Australia. Common benzodiazepines include Alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restoril).
Benzodiazepines are prescribed mainly for problems relating to anxiety and sleep, although they can also be used in the treatment of seizures, muscle spasms and in the management of alcohol and other drug withdrawal.
Data from the PBS indicate that in 2020–21, around 5.2 million benzodiazepine scripts were dispensed to 1.4 million patients. Diazepam had the highest rates of dispensing among benzodiazepine drugs. (source: AIHW)
Benzodiazepines have provided relief to countless individuals struggling with anxiety and insomnia, offering symptomatic relief and improving quality of life. Nevertheless, their long-term use can lead to dependence, addiction, and adverse effects. Some of the side effects include drowsiness, light-headedness, confusion, dizziness, and memory problems. Such side effects can have an impact at work.
Benzodiazepines can be detected in urine and some oral fluids workplace drug testing programs and therefore need to be addressed in a comprehensive Drug and Alcohol policy.
If you’d like to know more about benzodiazepines, come along to our “Benzodiazepines – Workplace Implications” webinar on Wednesday June 21st, click here to register.
For more information on benzodiazepines or any workplace drug and alcohol issue, call DASA on 1300 230 231.
DASA (Drug and Alcohol Solutions Australia) is proud to be leading the way in workplace drug and alcohol testing services throughout Australia. Whether your need is for workplace drug and workplace alcohol testing, advice on drug and alcohol policy or ideas on how to communicate your workplace expectations, policies and procedures to your staff, DASA can help. We have the experience, technical expertise and people to lead you to the right solution.
Comments